# Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers

> **NCT02183441** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1356
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT02183441
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183441, "Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*